Get the Stockscreener App
92.90
0.65%
-0.61
After Hours:
92.90
Overview
News
Price History
Option Chain
Financials
Why RVTY Down?
Discussions
Forecast
Stock Split
Dividend History
Revvity Inc stock is traded at $92.90, with a volume of 550.67K.
It is down -0.65% in the last 24 hours and up +8.57% over the past month.
Revvity is a global life sciences and diagnostics company formed in 2023 following the rebranding of PerkinElmer. The company operates in two segments: life sciences, which provides reagents and instruments for biopharma and academic research, and signals software, and diagnostics, which offers tools in immunodiagnostics and newborn and reproductive health. Revvity's products and services are sold worldwide, with major markets in the US, Europe, and China.
See More
Previous Close:
$93.51
Open:
$94.03
24h Volume:
550.67K
Relative Volume:
0.43
Market Cap:
$10.39B
Revenue:
$2.86B
Net Income/Loss:
$239.88M
P/E Ratio:
44.44
EPS:
2.0903
Net Cash Flow:
$506.94M
1W Performance:
+2.77%
1M Performance:
+8.57%
6M Performance:
+0.85%
1Y Performance:
-2.76%
1-Day Range:
$92.66
$94.96
1-Week Range:
$87.23
$94.96
52-Week Range:
$81.36
$118.30
Revvity Inc Stock (RVTY) Company Profile
Name
Revvity Inc
Sector
Industry
Phone
781-663-6900
Address
77 4TH AVENUE, WALTHAM
Compare RVTY vs TMO, DHR, IDXX, A, WAT
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RVTY
Revvity Inc
|
92.90 | 10.45B | 2.86B | 239.88M | 506.94M | 2.0903 |
TMO
Thermo Fisher Scientific Inc
|
531.67 | 195.93B | 44.56B | 6.72B | 6.29B | 17.74 |
DHR
Danaher Corp
|
198.14 | 140.56B | 24.57B | 3.60B | 5.26B | 5.051 |
IDXX
Idexx Laboratories Inc
|
580.76 | 46.39B | 4.30B | 1.06B | 1.04B | 13.08 |
A
Agilent Technologies Inc
|
119.77 | 34.02B | 7.07B | 1.29B | 993.00M | 4.5355 |
WAT
Waters Corp
|
326.20 | 32.49B | 3.17B | 642.63M | 516.49M | 10.77 |
Revvity Inc Stock (RVTY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-15-25 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-09-25 | Initiated | Goldman | Neutral |
| Oct-16-25 | Initiated | Guggenheim | Neutral |
| May-01-25 | Upgrade | UBS | Neutral → Buy |
| Jan-10-25 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Dec-13-24 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-15-24 | Upgrade | Barclays | Equal Weight → Overweight |
| Aug-28-24 | Initiated | Wells Fargo | Equal Weight |
| Jul-08-24 | Initiated | Leerink Partners | Outperform |
| Jun-03-24 | Resumed | Jefferies | Hold |
| Jan-16-24 | Downgrade | UBS | Buy → Neutral |
| Jan-04-24 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-19-23 | Initiated | Wells Fargo | Equal Weight |
| Dec-13-23 | Initiated | Wolfe Research | Peer Perform |
| Sep-28-23 | Initiated | Bernstein | Outperform |
| Jul-19-23 | Initiated | Raymond James | Outperform |
| May-23-23 | Resumed | Goldman | Buy |
View All
Revvity Inc Stock (RVTY) Latest News
Barclays Maintains Revvity(RVTY.US) With Hold Rating, Maintains Target Price $95 - Moomoo
RVTY Maintains Neutral Rating by Goldman Sachs -- Price Target L - GuruFocus
What to expect from Revvity's next quarterly earnings report - MSN
Barclays Downgrades Revvity(RVTY.US) to Hold Rating, Cuts Target Price to $95 - Moomoo
Barclays Downgrades Revvity to Equalweight From Overweight, Adjusts Price Target to $95 From $118 - marketscreener.com
Revvity Q1 2026 Earnings Forecast & Stock Analysis | Barchart ReportNews and Statistics - IndexBox
Revvity Inc. stock underperforms Monday when compared to competitors despite daily gains - MarketWatch
RVTY Unveils Signals BioDesign for Faster Molecular Cloning & R&D Data - Zacks Investment Research
TD Cowen Adjusts Price Target on Revvity to $115 From $124, Maintains Buy Rating - marketscreener.com
Goldman Sachs Adjusts Price Target on Revvity to $95 From $110, Maintains Neutral Rating - Moomoo
Revvity to Hold Earnings Call on Tuesday, May 5, 2026 - marketscreener.com
Rate Cut: Whats the beta of Revvity Inc stockWeekly Loss Report & Verified Trade Idea Suggestions - baoquankhu1.vn
Revvity launches Signals BioDesign to advance biologic research workflows - SelectScience
What to Expect From Revvity's Next Quarterly Earnings Report - Barchart.com
(RVTY) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Revvity Inc at Barclays Global Healthcare Conference Transcript - GuruFocus
Revvity Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
Revvity Schedules Q1 2026 Earnings Call - National Today
Published on: 2026-04-10 20:23:20 - baoquankhu1.vn
Revvity launches cloud-based molecular cloning software platform By Investing.com - Investing.com Canada
Revvity, Inc. (RVTY) Stock Price, News, Quote & History - Yahoo! Finance Canada
Revvity (RVTY) Launches Cloud-Based Molecular Cloning Solution - GuruFocus
Revvity (RVTY) Introduces New Cloud-Based Molecular Cloning Plat - GuruFocus
Revvity Launches Signals BioDesign Offering for Biologics Research Workflows - marketscreener.com
Revvity launches cloud-based molecular cloning software platform - Investing.com
Revvity Unveils its Signals BioDesign Offering to Advance Biologic Research Workflows - Yahoo Finance
RVTY Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Revvity Inc. stock outperforms competitors on strong trading day - MarketWatch
Swing Trade: Can Revvity Inc outperform in the next rallyLayoff News & Expert-Curated Trade Recommendations - baoquankhu1.vn
Revvity Sees Growth in Diagnostics, Encounters Challenges in China - Bitget
Revvity Gains on Diagnostics Strength, Faces China Headwinds - Yahoo Finance
Evercore ISI Adjusts Revvity Price Target to $108 From $118, Maintains Outperform Rating - marketscreener.com
Evercore Maintains Revvity(RVTY.US) With Buy Rating, Cuts Target Price to $108 - Moomoo
Tudor Investment Corp ET AL Purchases Shares of 172,601 Revvity Inc. $RVTY - MarketBeat
Revvity (RVTY) Valuation Check After Recent Share Price Momentum Shift - Yahoo Finance
META_TITLE_QUOTE - Yahoo Finance Singapore
Revvity at TD Cowen: Strategic Growth and Margin Expansion - Investing.com
Revvity, Inc. (RVTY) stock price, news, quote and history - Yahoo Finance UK
Baird Maintains Revvity (RVTY) Outperform Recommendation - MSN
Revvity, Inc. (RVTY) Stock Forecasts - Yahoo Finance
Here’s Artisan Mid Cap Value Fund’s Investment Thesis for Revvity (RVTY) - Yahoo Finance
Liquidity Mapping Around (RVTY) Price Events - Stock Traders Daily
Revvity CEO Acknowledges Challenges In Immunodiagnostics Business In China: Retail Terms Stock Drop An ‘Overreaction’ - MSN
JP Morgan Lowers Revvity (RVTY) Price Target to $96, Maintains N - GuruFocus
Revvity (NYSE:RVTY) Price Target Cut to $96.00 by Analysts at JPMorgan Chase & Co. - MarketBeat
J.P. Morgan Initiates Revvity(RVTY.US) With Hold Rating, Announces Target Price $96 - Moomoo
JPMorgan Adjusts Price Target on Revvity to $96 From $105, Maintains Neutral Rating - marketscreener.com
Allspring Global Investments Holdings LLC Raises Holdings in Revvity Inc. $RVTY - MarketBeat
Revvity Inc Stock (RVTY) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.41%
1.61%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):